Edition:
United States

Manojna Maddipatla

Allergan depression treatment fails studies, shares slip

Mar 06 2019

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.

Marriott revenue, FY forecast miss estimates on weak demand

Feb 28 2019

Marriott International Inc on Thursday missed Wall Street estimates for quarterly revenue and forecast a lower-than-expected full-year profit, blaming weak demand in North America, its largest market.

Medtronic quarterly profit beats on strength in surgical products

Feb 19 2019

Medtronic Plc beat analysts' estimates for quarterly profit on Tuesday, boosted by sales of its surgical products, and the largest U.S. standalone medical device maker raised the upper end of its full-year earnings forecast.

Merck's Keytruda tops $2 billion in quarterly sales, shares rise

Feb 01 2019

Merck & Co's cancer immumotherapy Keytruda compiled sales that topped $2 billion in a quarter for the first time, exceeding Wall Street's lofty estimates and sending shares up more that 3 percent on Friday.

Walgreens' cost-cut plans aim to save more than $1 billion annually

Dec 20 2018

Walgreens Boots Alliance Inc said on Thursday it would consolidate warehouses and shut some stores as part of a cost-cutting plan aimed at saving more than $1 billion annually.

U.S. healthcare stocks drop after judge rules Obamacare unconstitutional

Dec 17 2018

Shares of U.S. health insurers, hospitals and healthcare companies fell on Monday in the aftermath of a ruling by a federal judge in Texas that the Affordable Care Act (ACA), commonly called Obamacare, was unconstitutional.

UPDATE 3-Supernus Pharma's ADHD treatment fails to impress; shares fall

Dec 06 2018

Dec 6 Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 04 2018

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

World News